Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2025)
Historic Gross Margin for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to 95.26%.
- Zevra Therapeutics' Gross Margin rose 575000.0% to 95.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.66%, marking a year-over-year increase of 103700.0%. This contributed to the annual value of 68.59% for FY2024, which is 235000.0% down from last year.
- As of Q3 2025, Zevra Therapeutics' Gross Margin stood at 95.26%, which was up 575000.0% from 52.2% recorded in Q2 2025.
- Over the past 5 years, Zevra Therapeutics' Gross Margin peaked at 100.0% during Q3 2021, and registered a low of 19.69% during Q2 2024.
- For the 5-year period, Zevra Therapeutics' Gross Margin averaged around 85.26%, with its median value being 94.96% (2024).
- In the last 5 years, Zevra Therapeutics' Gross Margin tumbled by -723200bps in 2024 and then soared by 575000bps in 2025.
- Over the past 5 years, Zevra Therapeutics' Gross Margin (Quarter) stood at 97.71% in 2021, then grew by 1bps to 98.91% in 2022, then fell by -9bps to 90.5% in 2023, then decreased by -2bps to 88.63% in 2024, then rose by 7bps to 95.26% in 2025.
- Its Gross Margin was 95.26% in Q3 2025, compared to 52.2% in Q2 2025 and 93.41% in Q1 2025.